Dynogen Pharmaceuticals Inc.

Dynogen Pharmaceuticals Inc. is focusing on the neurological underpinnings of large, undermet GU and GI disorders including overactive bladder and irritable bowel syndrome. It is in-licensing clinical-stage compounds originally earmarked for CNS indications and developing them instead to modulate neurological targets involved in GU and GI function.